At The New York Times' Prescriptions blog, Andrew Pollack says RNA interference "might not be dead yet." That Alnylam Pharmaceuticals recently announced it had established proof of concept for the efficacy of an RNAi-based drug in a phase 1 clinical trial "at least points to the possibility that the approach can be used in people," Pollack says.